Drug shortages have sparked hearings, questions over why the US doesn’t do more domestic manufacturing, and the various causes. Now, a new bipartisan Senate bill is hoping to rein in the American’s dependence on foreign pharmaceuticals and APIs.
Sens. Joni Ernst (R-IA) and Gary Peters (D-MI) introduced the bill last week and it aims to limit foreign manufacturing for critical drugs and requires the DOD and the DHS to assess the vulnerabilities and other national security risks to the pharmaceutical supply chain.
The bill, known as the Pharmaceutical Supply Chain Risk Assessment Act, would also require the DOD, DHS and HHS to build on existing lists of critical drugs to also include at-risk populations and products that, if they were in shortage, would pose a “significant threat” to the nation’s healthcare system. This list in turn would be used to find drugs and ingredients that have…
Click here to view original post
